Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use
Current Oncology · 2025
DOI: 10.3390/curroncol32030128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Joanna Gotfrit und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Ottawa Hospital Cancer Centre (TOHCC), Ottawa, ON K1H 8L6, Canada. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Advanced pancreatic cancer results in high morbidity and mortality. The standard of care treatment in the advanced setting changed in 2011 with the introduction of FOLFIRINOX (FFX) chemotherapy. However, it was highly toxic with significant risk of complications. We assessed the practice patterns of medical oncologists across Canada.
Methods
We performed a retrospective study of consecutive patients with advanced pancreatic cancer treated with FFX at eight Canadian cancer centers. Demographic, treatment, and outcome data were collected and analyzed.
Results
The median age of the patients was 61 (range 24–80), 43% were female, 96% had an ECOG PS of 0 or 1, and 50% had three or more metastatic sites. The median follow-up time was 20.8 months (95%CI 18.6–24.9). Physicians started FFX at the standard dose 31% of the time. Physicians prescribed GCSF for primary prophylaxis most when giving standard-dose FFX (30% of the time) in comparison to reduced dose with or without the 5-FU bolus. Dose reductions occurred in 78.1% of patients, while dose delay occurred in 65.2% of patients.
Conclusions
Medical oncologists in Canada historically prescribed FFX to patients with advanced pancreatic cancer in a fashion that was not uniform, prior to the emergence of evidence for upfront dose reductions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Ottawa Hospital Cancer Centre (TOHCC), Ottawa, ON K1H 8L6, Canada.
- Unity Health, Toronto, ON M5B 1W8, Canada.
- Windsor Regional Hospital (WRH), Windsor, ON N8W 2X3, Canada.
- Jewish General Hospital (JGH), Montréal, QC H3T 1E2, Canada.
- Allan Blair Cancer Centre (ABCC), Regina, SK S4T 7T1, Canada.
- Saskatoon Cancer Center (SCC), Saskatoon, SK S7N 4H4, Canada.
ORCID-Profile: Horia Marginean, Haji Chalchal, Shahid Ahmed, Karen Mulder, Patricia Tang
Förderung
- Sanofi
Zitieren
APA
Gotfrit, J., Marginean, H., Ko, Y. J., Ghafoor, A., Kavan, P., Chalchal, H., Ahmed, S., Mulder, K., Tang, P., & Goodwin, R. (2025). Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use. Current Oncology. https://doi.org/10.3390/curroncol32030128
Vancouver
Gotfrit J, Marginean H, Ko YJ, Ghafoor A, Kavan P, Chalchal H, et al. Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use. Current Oncology. 2025. doi:10.3390/curroncol32030128
BibTeX
@article{Gotfrit2025,
author = {Gotfrit, Joanna and Marginean, Horia and Ko, Yoo-Joung and Ghafoor, Akmal and Kavan, Petr and Chalchal, Haji and Ahmed, Shahid and Mulder, Karen and Tang, Patricia and Goodwin, Rachel},
title = {Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32030128}
}
EUVIMED